Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Unlabeled Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Genes that may be involved
  • Substrate of
  • Drug Interactions
  • Nutrition/Nutraceutical Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Austria: Aldara; Belgium: Aldara; Bulgaria: Aldara; Czech Republic: Aldara; Denmark: Aldara; Estonia: Aldara; Finland: Aldara; France: Aldara; Germany: Aldara; Greece: Aldara; Hungary: Aldara; Ireland: Aldara; Italy: Aldara; Latvia: Aldara; Lithuania: Aldara; Luxembourg: Aldara; Malta: Aldara; Netherlands: Aldara; Poland: Aldara; Portugal: Aldara; Romania: Aldara; Slovakia: Aldara; Slovenia: Aldara; Spain: Aldara; Sweden: Aldara; UK: Aldara.

North America

Canada: Aldara, Zyclara; USA: Aldara, Imiquimod, Zyclara.

Latin America

Argentina: Imimore, Miquimod, Modulcass, Quinilan, Virosupril; Brazil: Aldara, Ixium; Mexico: Aldara, Imiquimod, Vetland.


Japan: Aldara.

Drug combinations


Imiquimod: C~14~H~16~N~4~. Mw: 240.3. (1) 4-Amino-1-isobutyl-1H-imidazo[4,5-c]quinoline; (2) 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine. CAS-99011-02-6.

Pharmacologic Category

Skin and Mucous Membrane Agents, Miscellaneous. Topical Skin Product. (ATC-Code: D06BB10).

Mechanism of action

The mechanism of action in treating actinic keratosis (AK) and superficial basal cell carcinoma (sBCC) lesions is unknown.

Therapeutic use

Treatment of external genital and perianal warts/condyloma acuminata; nonhyperkeratotic, nonhypertrophic AK on face or scalp; sBCC with a maximum tumor diameter of 2 cm located on the trunk, neck, or extremities (excluding hands or feet).

Pregnancy and lactiation implications

Safety and efficacy have not been established in pregnant women. A registry has been established for women exposed to imiquimod during pregnancy. Not recommended during lactation.

Unlabeled use

Treatment of common warts.


Hypersensitivity to the active substance or to any of the excipients.

Warnings and precautions

Imiquimod has the potential to exacerbate inflammatory conditions of the skin (should be used with caution in patients with autoimmune conditions). Imiquimod cream should be used with caution in organ transplant patients. Not recommended until skin has healed after any previous drug or surgical treatment. Occlusive dressing not recommended with imiquimod cream therapy. The excipients methylhydroxybenzoate, propylhydroxybenzoate, cetyl alcohol and stearyl alcohol may cause allergic reactions. Intense local inflammatory reactions including skin weeping or erosion can occur (may be accompanied, or even preceded, by flu-like systemic signs and symptoms including malaise, pyrexia, nausea, myalgias and rigors; an interruption of dosing should be considered). Should be used with caution in patients with reduced hematologic reserve. Severe local inflammatory reactions of the female external genitalia can lead to severe vulvar swelling, and this to urinary retention (dosing should be interrupted or discontinued). Avoid exposure to sunlight and sunlamps. Safety and efficacy not established for repeat courses of treatment to the same area for AK. Not recommended for treatment of BCC subtypes other than the superficial variant. Treatment of urethral, intra-vaginal, cervical, rectal or intra-anal viral disease not recommended. Safety and efficacy in immunosuppressed patients not established.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart